Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.

Amaranth Medical Bioresorbable Scaffold, Fortitude stent
News | Stents Bioresorbable | October 16, 2015
October 16, 2015 — Enrollment has successfully concluded in its multi-center, international CE mark clinical trials...
Synergy stent
Technology | October 05, 2015
October 5, 2015 — The U.S. Food and Drug Administration (FDA) has approved Boston Scientific’s Synergy Bioabsorbable...
Xposition S, Stentys, SETUP trial, results, EuroPCR, EuroIntervention

Xposition S image courtesy of Stentys

News | Stents Drug Eluting | June 17, 2015
June 17, 2015 - Stentys announced that the findings of the first Xposition clinical experience, as part of the SETUP...
electronic stents, bioresorbable electronic stent, BES

An illustration of the bioresorbable electronic stent developed in the Korean study. It uses a magnesium stent which doubles as a wireless transmission antenna, flexible microelectronic sensors for blood flow and temperature, and a polylactic acid polymer coating with embedded drug-filled nanospheres that release the drug only when stimulated by heat or light. Image from ACS Nano.

Feature | Stents | May 28, 2015 | Dave Fornell
With the recent innovation of flexible microelectronic sensor circuits that can be made from bioresorbable materials,...
OrbusNeich, Combo, EPC, HARMONEE study, U.S.
News | May 28, 2015
May 28, 2015 — OrbusNeich has announced that the first U.S. patient has been enrolled in the HARMONEE (Harmonized...
Boston Scientific, Synergy, EVOLVE I, EVOLVE II, EuroPCR 2015, results
News | May 22, 2015
May 22, 2015 — Boston Scientific reported positive, long-term data from the EVOLVE Trial of the Synergy everolimus-...
Boston Scientific, investors, cardiology, growth, expansion
News | May 11, 2015
May 11, 2015 — Boston Scientific Corp. presented an overview of its continued business momentum and long-term growth...
BEST Trial
Feature | March 25, 2015
March 25, 2015 — Despite the advent of a new generation of stents, patients with multiple narrowed arteries in the...
Medtronic, Drug Filled Stent, clinical trial, ACC
Feature | March 16, 2015
March 16, 2015 — Medtronic plc unveiled the preclinical outcomes of its novel Drug-Filled Stent (DFS) at the 64th...
OrbusNeich, Combo Dual Therapy Stent, REMEDEE, EGO COMBO, JIM 2015

Image courtesy of OrbusNeich

News | March 06, 2015
March 6, 2015 — A three-year review of data on the Combo Dual Therapy Stent was presented at the Joint Interventional...
MiStent SES, Micell Technologies, Europe, bioresorbable stents
News | February 17, 2015
February 17, 2015 — Micell Technologies, Inc. announced the commercial availability of the MiStent sirolimus-eluting...
Blog | January 21, 2015
The America College of Cardiology has released its list of key late-breaking clinical trials at the ACC 2015 meeting in...
InspireMD, MGuard, CGuard, drug-eluting stent, MASTER II, CARENET, trials

MGuard image courtesy of InspireMD

News | January 05, 2015
January 5, 2015 — InspireMD, Inc. announced results from two important clinical trials. Thirty-day results from the...
bioresorbable stents

Abbott's Absorb bioresorbable stent

Feature | December 31, 2014 | Dave Fornell
Ongoing clinical trials of bioresorbable stents continue to show positive data for the devices, which are widely...
Boston Scientific, EVOLVE II, Synergy, bioresorbable stent
News | December 10, 2014
December 10, 2014 — In the first successful United States trial of a bioabsorbable polymer stent, the Boston Scientific...